Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 350

1.

Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial.

Kooij JJ, Rösler M, Philipsen A, Wächter S, Dejonckheere J, van der Kolk A, van Agthoven M, Schäuble B.

BMC Psychiatry. 2013 Jan 24;13:36. doi: 10.1186/1471-244X-13-36.

2.

Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.

Buitelaar JK, Sobanski E, Stieglitz RD, Dejonckheere J, Waechter S, Schäuble B.

J Clin Psychiatry. 2012 Aug;73(8):1097-102. doi: 10.4088/JCP.11m07528. Epub 2012 Jun 12.

PMID:
22780962
3.

Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate.

Buitelaar JK, Kooij JJ, Ramos-Quiroga JA, Dejonckheere J, Casas M, van Oene JC, Schäuble B, Trott GE.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):554-60. doi: 10.1016/j.pnpbp.2010.12.016. Epub 2010 Dec 23.

PMID:
21185347
4.

Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study.

Casas M, Rösler M, Sandra Kooij JJ, Ginsberg Y, Ramos-Quiroga JA, Heger S, Berwaerts J, Dejonckheere J, van der Vorst E, Schäuble B.

World J Biol Psychiatry. 2013 May;14(4):268-81. doi: 10.3109/15622975.2011.600333. Epub 2011 Nov 22.

PMID:
22106853
5.

Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate.

Buitelaar JK, Casas M, Philipsen A, Kooij JJ, Ramos-Quiroga JA, Dejonckheere J, van Oene JC, Schäuble B.

Psychol Med. 2012 Jan;42(1):195-204. doi: 10.1017/S0033291711000845. Epub 2011 Jun 1.

6.

A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.

Takahashi N, Koh T, Tominaga Y, Saito Y, Kashimoto Y, Matsumura T.

World J Biol Psychiatry. 2014 Aug;15(6):488-98. doi: 10.3109/15622975.2013.868925. Epub 2014 Jan 23.

PMID:
24456065
7.

Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate.

Rösler M, Ginsberg Y, Arngrim T, Adamou M, Niemelä A, Dejonkheere J, van Oene J, Schäuble B.

World J Biol Psychiatry. 2013 May;14(4):282-90. doi: 10.3109/15622975.2011.571283. Epub 2011 Apr 26.

PMID:
21517701
8.

Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.

Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.

J Clin Psychopharmacol. 2009 Jun;29(3):239-47. doi: 10.1097/JCP.0b013e3181a390ce.

PMID:
19440077
10.

Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.

Jain U, Hechtman L, Weiss M, Ahmed TS, Reiz JL, Donnelly GA, Harsanyi Z, Darke AC.

J Clin Psychiatry. 2007 Feb;68(2):268-77.

PMID:
17335326
11.

A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T.

Biol Psychiatry. 2006 May 1;59(9):829-35. Epub 2005 Dec 20. Erratum in: Biol Psychiatry. 2007 Jun 15;61(12):1402.

PMID:
16373066
12.

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.

Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G.

Pediatrics. 2001 Oct;108(4):883-92.

PMID:
11581440
13.

A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Trott GE, Lee E, Buitelaar JK.

Biol Psychiatry. 2008 May 15;63(10):981-9. doi: 10.1016/j.biopsych.2007.11.008. Epub 2008 Jan 22.

PMID:
18206857
14.

Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD.

Buitelaar JK, Trott GE, Hofecker M, Waechter S, Berwaerts J, Dejonkheere J, Schäuble B.

Int J Neuropsychopharmacol. 2012 Feb;15(1):1-13. doi: 10.1017/S1461145711001131. Epub 2011 Jul 29.

15.

Treatment adherence and persistence in adult ADHD: results from a twenty-four week controlled clinical trial with extended release methylphenidate.

Sobanski E, Retz W, Fischer R, Ose C, Alm B, Hennig O, Rösler M.

Eur Psychiatry. 2014 Jun;29(5):324-30. doi: 10.1016/j.eurpsy.2013.08.004. Epub 2013 Oct 29.

PMID:
24176644
16.
17.

Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.

Kordon A, Stollhoff K, Niederkirchner K, Mattejat F, Rettig K, Schäuble B.

Postgrad Med. 2011 Sep;123(5):27-38. doi: 10.3810/pgm.2011.09.2457.

PMID:
21904084
19.

A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder.

Findling RL, Bukstein OG, Melmed RD, López FA, Sallee FR, Arnold LE, Pratt RD.

J Clin Psychiatry. 2008 Jan;69(1):149-59. Erratum in: J Clin Psychiatry. 2008 Feb;69(2):329.

PMID:
18312050
20.

Are stimulants effective in the treatment of executive function deficits? Results from a randomized double blind study of OROS-methylphenidate in adults with ADHD.

Biederman J, Mick E, Fried R, Wilner N, Spencer TJ, Faraone SV.

Eur Neuropsychopharmacol. 2011 Jul;21(7):508-15. doi: 10.1016/j.euroneuro.2010.11.005. Epub 2011 Mar 9.

PMID:
21303732

Supplemental Content

Support Center